AHS Hospital Corp.

Consolidated Financial Statements and Supplemental Information December 31, 2024 and 2023

AHS Hospital Corp.

Index

December 31, 2024 and 2023

	Page(s)
Report of Independent Auditors	1–2
Consolidated Financial Statements	
Balance Sheets	3
Statements of Operations	4
Statements of Changes in Net Assets	5
Statements of Cash Flows	6
Notes to Financial Statements	7–41
Supplemental Information	
Consolidating Statements of Operations	42-43
Note to Consolidating Supplemental Information	44



Report of Independent Auditors

To the Board of Trustees of Atlantic Health System, Inc.

Opinion

We have audited the accompanying consolidated financial statements of AHS Hospital Corp. and its subsidiaries (the "Company"), which comprise the consolidated balance sheets as of December 31, 2024 and 2023, and the related consolidated statements of operations, of changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "consolidated financial statements").

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing an
 opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is
 expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements taken as a whole. The accompanying consolidating statements of operations for the years ended December 31, 2024 and 2023 (the "supplemental information") is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. The consolidating information is not intended to present, and we do not express an opinion on, the financial position, results of operations, changes in net assets and cash flows of the individual divisions of the Company. The supplemental information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The supplemental information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the consolidated financial statements taken as a whole.

New York, New York

Pricuvaterhouse Coopers LIP

April 11, 2025

AHS Hospital Corp. Consolidated Balance Sheets December 31, 2024 and 2023

(in thousands)		2024		2023
Assets				
Current assets Cash and cash equivalents Assets limited as to use Patient accounts receivable, net Other current assets	\$	244,580 67,872 465,950 278,957	\$	516,839 68,070 386,450 231,841
Total current assets		1,057,359		1,203,200
Assets limited as to use, net of current portion Long-term investments and other assets Property, plant and equipment, net Right of use assets, net		2,804,958 601,626 1,534,904 347,760		2,590,977 532,377 1,406,676 304,031
Total assets	\$	6,346,607	\$	6,037,261
Liabilities and Net Assets Current liabilities	Φ	40.426	ф	40.400
Current portion of long-term debt Current portion of lease liability Accounts payable and accrued expenses Estimated amounts due to third party payers	\$	19,136 49,576 565,117 57,841	\$	18,486 42,107 529,614 67,193
Total current liabilities		691,670		657,400
Accrued employee benefits and other, net of current portion Long-term debt, net of unamortized bond premium,		291,637		299,337
debt issuance costs, and current portion Long-term lease liability, net of current portion		1,366,897 308,001		1,386,033 270,571
Total liabilities		2,658,205		2,613,341
Net assets Without donor restrictions controlled by the Hospital Without donor restrictions attributable to noncontrolling interests		3,460,230 4,244		3,208,705 4,244
Without donor restrictions		3,464,474		3,212,949
With donor restrictions	_	223,928		210,971
Total net assets		3,688,402		3,423,920
Total liabilities and net assets	\$	6,346,607	\$	6,037,261

AHS Hospital Corp. Consolidated Statements of Operations Years Ended December 31, 2024 and 2023

(in thousands)	2024	2023
Revenues, gains and other support		
Net patient service revenue	\$ 4,308,381	\$ 3,913,906
Other revenue	47,751	39,554
Legislative funding from FEMA	872	29,424
Net assets released from restrictions	15,827	15,283
Total revenues, gains and other support	4,372,831	3,998,167
Expenses		
Salaries	2,021,210	1,831,954
Supplies and other expenses	1,598,603	1,445,666
Employee benefits	410,607	344,650
Depreciation and amortization	183,188	178,965
Interest	55,792	51,355
Total operating expenses	4,269,400	3,852,590
Operating income	103,431	145,577
Change in net unrealized gains	69,325	289,748
Investment income, net	150,402	60,394
Nonoperating loss, net	(5,697)	(17,063)
Excess of revenues over expenses	317,461	478,656
Other changes in net assets without donor restrictions		
Noncontrolling interest	-	(396)
Equity transfers to related parties	(157,918)	(28,676)
Change in funded status of benefit plans	16,018	35,312
Net assets released from restrictions for capital purposes	21,006	18,266
Government grants used for capital purchases	54,958	47,079
Increase in net assets without		
donor restrictions	\$ 251,525	\$ 550,241

AHS Hospital Corp. Consolidated Statements of Changes in Net Assets Years Ended December 31, 2024 and 2023

(in thousands)	2024	2023
Net assets without donor restrictions		
Excess of revenues over expenses	\$ 317,461	\$ 478,656
Noncontrolling interest	-	(396)
Equity transfers to related parties	(157,918)	(28,676)
Change in funded status of benefit plans	16,018	35,312
Net assets released from restrictions for capital purposes	21,006	18,266
Government grants used for capital purchases	 54,958	 47,079
Increase in net assets without		
donor restrictions	 251,525	550,241
Net assets with donor restrictions		
Contributions	43,809	33,837
Investment income	2,033	1,644
Change in net unrealized gain	3,948	5,143
Net assets released from restrictions for operations	(15,827)	(15,283)
Net assets released from restrictions for capital purposes	 (21,006)	(18,266)
Increase in net assets with donor restrictions	12,957	7,075
Increase in net assets	264,482	557,316
Net assets		
Beginning of year	3,423,920	2,866,604
End of year	\$ 3,688,402	\$ 3,423,920

AHS Hospital Corp. Consolidated Statements of Cash Flows Years Ended December 31, 2024 and 2023

Cash flows from operating activities (\$ 264,84 \$ 557,81) Change in net assets to reconcile change in net assets to net cash provided by operating activities (\$ 16,000 \$ 13,000 \$	(in thousands)	2024	2023
Aglustments for reconcile change in net assets to net cash provided by operating activities (16,018) (35,312) Change in funded status of benefit plans (16,018) (35,312) Equily transfers to related partiles 157,918 28,676 Depreciation and amortization 129 12 Neconotrolling interest 16,637 (284,986) Net realized and unrealized (gains) on investments (16,537) (15,448) Change in value of swap agreements (15,73) (15,448) Amortization of deferred financing costs and bond premiums (2,352) 42,552 Amortization of right of use assets (85,631) (37,782) Crants and contributions restricted for capital purposes and permanent investments (78,989) (65,180) Changes in assets and liabilities (81,138) (40,828) Increase in nother assets (85,631) (37,852) Decrease in accounts payable, accrued expenses, estimated amounts (85,631) (78,887) Decrease in Accounts payable, accrued employee benefits and other liabilities (19,887) (56,340) Net cash provided by operating activities (16,86151) (2,556,888)	Cash flows from operating activities		
coperating activities (16.018) 3(35.21) Change in funded status of benefit plans (16.018) 28.076 Depreciation and anortization 183.188 179.985 Loss on disposal of property, plant and equipment 129 12 Non-controlling interest (146.537) (287.496) Net realized and unrealized (gains) on investments (146.537) (287.496) Change in value of swap agreements (15.73) (15.44) Amortization of deferred financing costs and bond premiums (2.352) (2.352) Amortization of inpit of use assets (81.308) (65.180) Changes in net patient accounts receivable (81.318) (40.028) Increase in nother assets (85.631) (37.852) Decrease in cARES Act Medicare advancements (85.631) (37.852) Decrease in caccounts payable, accrued expenses, estimated amounts (19.867) (56.340) Decrease in CARES Act Medicare advancements (19.866.151) (25.568.88) Decrease in case of investments (19.867) (56.340) Net cash provided by operating activities (19.867) (25.568.88)	Change in net assets	\$ 264,482	\$ 557,316
Change in funded status of benefit plans 28.512 28.000 28.	Adjustments to reconcile change in net assets to net cash provided by	•	•
Equity transfers to related parties 157,918 28,676 180,185 178,965 180,185 178,965 180,185 181,185	operating activities		
Equity transfers to related parties 157,918 28,676 180,185 178,965 180,185 178,965 180,185 181,185	Change in funded status of benefit plans	(16,018)	(35,312)
Descendisposal of property, plant and equipment 129 12 12 136	Equity transfers to related parties	157,918	28,676
Noncontrolling interest (396) Net realized and unrealized (gains) on investments (146,537) (287,496) Change in value of swap agreements (1,573) (1,544) Amortization of deferred financing costs and bond premiums (2,352) (2,352) Amortization of right of use assets (48,637) 37,718 Grants and contributions restricted for capital purposes and permanent investments (78,989) (65,180) Changes in assets and liabilities (81,138) (40,828) Increase in net patient accounts receivable (81,138) (40,828) Increase in other assets (85,631) (37,852) Decrease in CARES Act Medicare advancements (85,631) (37,852) Decrease in cocourts payable, accrued expenses, estimated amounts (19,887) (56,340) Net cash provided by operating activities 221,842 28,966 Purchases of investments (10,887) (25,568,88) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,55	Depreciation and amortization	183,188	178,965
Net realized and unrealized (gains) on investments (146,537) (287,496) Change in value of swap agreements (1,573) (1,544) Amortization of deferred financing costs and bond premiums (2,352) (2,352) Amortization of deferred financing costs and bond premiums (48,250) 37,718 Grants and contributions restricted for capital purposes and permanent investments (76,998) (65,180) Changes in assets and liabilities (81,138) (40,828) Increase in net patient accounts receivable (81,138) (40,828) Increase in other assets (6,618) (6,618) Decrease in charts acts (6,618) (6,618) Decrease in accounts payable, accrued expenses, estimated amounts (19,887) (56,340) Net cash provided by operating activities (19,887) (56,340) Purchases of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Repayment of loan to CartaState <td>Loss on disposal of property, plant and equipment</td> <td>129</td> <td>12</td>	Loss on disposal of property, plant and equipment	129	12
Change in value of swap agreements (1,573) (1,544) Amortization of deferred financing costs and bond premiums (2,352) (2,352) Amortization of right of use assets 48,250 37,718 Grants and contributions restricted for capital purposes and permanent investments (78,999) (65,180) Changes in net patient accounts receivable (81,138) (40,828) Increase in nother assets (85,631) (37,852) Decrease in CARES Act Medicare advancements - (6,418) Decrease in CARES Act Medicare advancements - (6,418) Decrease in counts payable, accrued expenses, estimated amounts (19,887) (56,340) Net cash provided by operating activities 221,842 268,969 Cash flows from investing activities (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,606,029) 2,501,800 Repayment of loan to AHSIC (5,340) (1,500,029) 2,501,800 Loan issued to AHSIC<	Noncontrolling interest	-	(396)
Amortization of deferred financing costs and bond premiums (2,352) (2,352) 37,78 Amortization of right of use assets 48,250 37,78 (65,180) 37,78 (65,180) (65,180) (65,180) (65,180) (65,180) (65,180) (65,180) (81,138) (40,828) (81,138) (40,828) (81,138) (40,828) (81,138) (40,828) (81,138) (40,828) (81,138) (40,828) (81,138) (40,828) (81,631) (37,852) (64,18) (81,631) (37,852) (64,18) (81,631) (37,852) (64,18) (64,18) (64,18) (64,18) (64,18) (64,18) (64,18) (64,18) (64,18) (64,18) (64,18) (64,18) (64,18) (65,40) (65,40) (65,40) (65,40) (65,40) (66,40) (66,40) (66,40) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,48) (66,	Net realized and unrealized (gains) on investments	(146,537)	(287,496)
Amortization of right of use assets 37.71s Grants and contributions restricted for capital purposes and permanent investments 78,989 (65,180) Changes in assets and liabilities (81,138) 4(4,028) Increase in net patient accounts receivable (81,38) 3(3,7852) Decrease in other assets (6,418) (6,418) Decrease in Laccounts payable, accrued expenses, estimated amounts (19,887) (56,340) due to third party payers, accrued employee benefits and other liabilities (19,887) 268,969 Cash flows from investing activities 221,842 268,969 Proceeds from sales of investments (1,686,151) (2,556,88) Repayment of loan to AHSIC 6,548 5,146 Loan issued to AHSIC 6,548 1,180 Contributions to venture capital private equity funds (3,11,927) (27,565) Contributions to venture	Change in value of swap agreements	(1,573)	(1,544)
Grants and contributions restricted for capital purposes and permanent investments (78,989) (65,180) Changes in assests and liabilities (81,138) (40,828) Increase in net patient accounts receivable (85,631) (37,852) Decrease in CARES Act Medicare advancements 6(81,188) (63,180) Decrease in accounts payable, accrued expenses, estimated amounts (19,887) (56,340) Met cash provided by operating activities 221,842 288,969 Purchases of investing activities (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Pocautifustion of Advanced Care Oncology & Hematology Associates (20,000) (10,000) Repayment of loan to Central State (20,000) (2,766) Addit	Amortization of deferred financing costs and bond premiums	(2,352)	(2,352)
Charges in assets and liabilities (81,138) (40,888) (10,788) (10,785) (10,78	Amortization of right of use assets	48,250	37,718
Increase in net patient accounts receivable (81,138) (30,828) Increase in other assets (85,631) (37,852) Cecrease in accounts payable, accrued expenses, estimated amounts (19,887) (56,340)	Grants and contributions restricted for capital purposes and permanent investments	(78,989)	(65,180)
Increase in other assets	Changes in assets and liabilities		
Decrease in ARRES Act Medicare advancements (6,418) Decrease in accounts payable, accrued expenses, estimated amounts due to third party payers, accrued employee benefits and other liabilities (19,887) (56,340) Net cash provided by operating activities 221,842 228,899 Cash flows from investing activities (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,606,029) 2,501,800 Repayment of loan to AHSIC 6,548 5,146 Loan issued to CentraState (20,000) (10,000) Repayment of loan to CentraState (20,000) (10,000) Repayment of loan to CentraState (20,000) (10,000) Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities (398,117) (325,638) Principal payments on line of credit (200,000) - Principal payments on long-term debt	Increase in net patient accounts receivable	(81,138)	(40,828)
Decrease in accounts payable, accrued expenses, estimated amounts due to third party payers, accrued employee benefits and other liabilities (19,887) (56,340) Net cash provided by operating activities 221,842 268,969 Cash flows from investing activities 1 (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,029) 2,501,800 Repayment of loan to AHSIC 6,548 5,146 Coan issued to AHSIC (20,000) (10,000) Repayment of loan to CentraState (20,000) (10,000) Repayment of loan to CentraState (2,786) (13,871) Contributions to venture capital private equity funds (2,786) (13,871) Contributions to venture capital private equity funds (2,786) (13,871) Additions to property, plant and equipment (20,000) (275,653) Additions to property, plant and equipment (200,000) (275,653) About such used in investing activities (200,000) (200,000) Principal payments on line of credit (200,000) (200,000) Canta and cont	Increase in other assets	(85,631)	(37,852)
due to third party payers, accrued employee benefits and other liabilities (19,887) (56,340) Net cash provided by operating activities 221,842 268,969 Cash flows from investing activities 8 Purchases of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,686,151) (2,556,888) Proceeds from sales of investments (1,606,029) 2,501,800 Repayment of loan to AHSIC 6,548 5,146 Loan issued to AHSIG (2,000) (10,000) Repayment of loan to CentraState (20,000) (10,000) Repayment of loan to CentraState (2,786) (13,871) Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) (275,653) Act cash used in investing activities (39,11) (275,653) Act cash used in investing activities 200,000 - Principal payments on line of credit (200,000) - Principal payments on line of credit (200,000) - Grain and contributions restricted	Decrease in CARES Act Medicare advancements	-	(6,418)
Net cash provided by operating activities 221,842 268,969 Cash flows from investing activities (1,686,151) (2,556,888) Proceeds from sales of investments 1,060,029 2,501,800 Repayment of loan to AHSIC 6,548 5,146 Loan issued to AHSIC (2,000) (10,000) Repayment of loan to CentraState (20,000) (10,000) Repayment of loan to CentraState (2,786) (13,871) Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) (275,663) Net cash used in investing activities (311,927) (275,653) Net cash used in investing activities 200,000 - Proceeds from line of credit 200,000 - Principal payments on line of credit 200,000 - Principal payments on line of credit (14,368) (15,533) Equity transfers to related parties (34,86) (34,86) Forats and contributions restricted for capital purposes and permanent investments 63,218 43,488 Pube	Decrease in accounts payable, accrued expenses, estimated amounts		
Cash flows from investing activities Purchases of investments (1,686,151) (2,556,888) Proceeds from sales of investments 1,606,029 2,501,800 Repayment of loan to AHSIC 6,548 5,146 Loan issued to AHSIC - (82,567) Loan issued to CentraState (20,000) (10,000) Repayment of loan to CentraState 19,681 - Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities 3(39,117) (432,033) Principal payments on line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on line of credit (200,000) - Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) <td>due to third party payers, accrued employee benefits and other liabilities</td> <td> (19,887)</td> <td> (56,340)</td>	due to third party payers, accrued employee benefits and other liabilities	 (19,887)	 (56,340)
Purchases of investments (1,686,151) (2,556,888) Proceeds from sales of investments 1,606,029 2,501,800 Repayment of loan to AHSIC 6,548 5,146 Loan issued to AHSIC (20,000) (10,000) Repayment of loan to CentraState (20,000) (10,000) Repayment of loan to CentraState (20,000) (10,000) Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Additions from financing activities (398,117) (432,033) Net cash used in investing activities 200,000 - Principal payments on line of credit (200,000) - Principal payments on line of credit (200,000) - Principal payments on line of credit (16,133) (15,533) Equity transfers to related parties (143,06) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net c	Net cash provided by operating activities	 221,842	 268,969
Proceeds from sales of investments 1,606,029 2,501,800 Repayment of loan to AHSIC 6,548 5,146 Loan issued to AHSIC - (82,567) Loan issued to CentraState (20,000) (10,000) Repayment of loan to CentraState 19,681 - Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities (398,117) (432,033) Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468	Cash flows from investing activities		
Repayment of loan to AHSIC 6,548 5,146 Loan issued to AHSIC (82,567) Loan issued to CentraState (20,000) (10,000) Repayment of loan to CentraState 19,681 - Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities 398,117 (432,033) Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (27,259) (163,805) Beginning of year 516,839 680,644	Purchases of investments	(1,686,151)	(2,556,888)
Loan issued to AHSIC (82,567) Loan issued to CentraState (20,000) (10,000) Repayment of loan to CentraState 19,681 - Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities 398,117 (432,033) Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (95,984) (741) Decrease in cash and cash equivalents 516,839 680,644 Eeginning of year 516,839 561,839 <td>Proceeds from sales of investments</td> <td>1,606,029</td> <td>2,501,800</td>	Proceeds from sales of investments	1,606,029	2,501,800
Loan issued to CentraState (20,000) (10,000) Repayment of loan to CentraState 19,681 - Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Additions to property, plant and equipment (398,117) (432,033) Net cash used in investing activities 200,000 - Proceeds from line of credit (200,000) - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents 295,984) (741) Decrease in cash and cash equivalents 516,839 680,644 Eeginning of year 516,839 680,644 End of t	Repayment of loan to AHSIC	6,548	5,146
Repayment of loan to CentraState 19,681 - Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities 398,117 (432,033) Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents \$16,839 680,644 End of the year \$16,839 516,839 Supplemental disclosure of cash flow information \$51,908 516,839 Cash paid for interest <td< td=""><td>Loan issued to AHSIC</td><td>-</td><td>(82,567)</td></td<>	Loan issued to AHSIC	-	(82,567)
Contributions to venture capital private equity funds (2,786) (13,871) Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities (398,117) (432,033) Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents 516,839 680,644 End of the year 516,839 516,839 Supplemental disclosure of cash flow information \$56,198 51,908 Cash paid for interest \$56,198 51,908 Increase in accruals for acquisition of pr	Loan issued to CentraState	(20,000)	(10,000)
Acquisition of Advanced Care Oncology & Hematology Associates (9,511) - Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities (398,117) (432,033) Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents (272,259) (163,805) End of the year 516,839 680,644 End of the year 516,839 516,839 Supplemental disclosure of cash flow information Cash paid for interest \$56,198 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (Repayment of loan to CentraState	19,681	-
Additions to property, plant and equipment (311,927) (275,653) Net cash used in investing activities (398,117) (432,033) Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents 516,839 680,644 End of the year 516,839 516,839 Supplemental disclosure of cash flow information Cash paid for interest 56,198 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Contributions to venture capital private equity funds	(2,786)	(13,871)
Net cash used in investing activities (398,117) (432,033) Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents 516,839 680,644 End of the year \$244,580 \$516,839 Supplemental disclosure of cash flow information \$56,198 \$1,908 Cash paid for interest \$56,198 \$1,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Acquisition of Advanced Care Oncology & Hematology Associates	(9,511)	-
Cash flows from financing activities Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents 516,839 680,644 End of the year 516,839 680,644 End of the year \$56,198 \$16,839 Supplemental disclosure of cash flow information Cash paid for interest \$56,198 \$1,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Additions to property, plant and equipment	 (311,927)	 (275,653)
Proceeds from line of credit 200,000 - Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents 516,839 680,644 End of the year 516,839 680,644 End of the year \$244,580 \$516,839 Supplemental disclosure of cash flow information \$56,198 \$51,908 Cash paid for interest \$56,198 \$51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Net cash used in investing activities	(398,117)	(432,033)
Principal payments on line of credit (200,000) - Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents 516,839 680,644 End of the year \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information \$ 56,198 \$ 51,908 Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Cash flows from financing activities		
Principal payments on long-term debt (16,133) (15,533) Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents Beginning of year 516,839 680,644 End of the year \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Proceeds from line of credit	200,000	-
Equity transfers to related parties (143,069) (28,676) Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents Seginning of year 516,839 680,644 End of the year \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information \$ 56,198 \$ 51,908 Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Principal payments on line of credit	(200,000)	-
Grants and contributions restricted for capital purposes and permanent investments 63,218 43,468 Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents 8 516,839 680,644 End of the year \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information \$ 56,198 \$ 51,908 Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Principal payments on long-term debt	(16,133)	(15,533)
Net cash used in financing activities (95,984) (741) Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents *** Beginning of year** End of the year** Supplemental disclosure of cash flow information \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information *** Cash paid for interest** Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Equity transfers to related parties	(143,069)	(28,676)
Decrease in cash and cash equivalents (272,259) (163,805) Cash and cash equivalents 516,839 680,644 End of the year \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information \$ 56,198 \$ 51,908 Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Grants and contributions restricted for capital purposes and permanent investments	 63,218	 43,468
Cash and cash equivalents Beginning of year 516,839 680,644 End of the year \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Net cash used in financing activities	 (95,984)	 (741)
Beginning of year 516,839 680,644 End of the year \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Decrease in cash and cash equivalents	(272,259)	(163,805)
End of the year \$ 244,580 \$ 516,839 Supplemental disclosure of cash flow information Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment \$ (9,026) \$ (4,561) Right of use assets obtained in exchange for operating lease obligations \$ 99,646 \$ 20,910	Cash and cash equivalents		
Supplemental disclosure of cash flow information Cash paid for interest \$ 56,198 \$ 51,908 Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	Beginning of year	 516,839	 680,644
Cash paid for interest\$ 56,198\$ 51,908Increase in accruals for acquisition of property, plant, and equipment(9,026)(4,561)Right of use assets obtained in exchange for operating lease obligations99,64620,910	End of the year	\$ 244,580	\$ 516,839
Cash paid for interest\$ 56,198\$ 51,908Increase in accruals for acquisition of property, plant, and equipment(9,026)(4,561)Right of use assets obtained in exchange for operating lease obligations99,64620,910	Supplemental disclosure of cash flow information		
Increase in accruals for acquisition of property, plant, and equipment (9,026) (4,561) Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	• •	\$ 56,198	\$ 51,908
Right of use assets obtained in exchange for operating lease obligations 99,646 20,910	•		
		, ,	
			-

The accompanying notes are an integral part of these consolidated financial statements.

(in thousands)

1. Organization

AHS Hospital Corp. and subsidiaries (the "Hospital") is a New Jersey not-for-profit entity comprised of five hospital facilities, the Morristown Medical Center ("Morristown Division"), the Overlook Medical Center ("Overlook Division"), the Newton Medical Center ("Newton Division"), the Chilton Medical Center ("Chilton Division"), and the Hackettstown Medical Center ("Hackettstown Division"). Atlantic Visiting Nurse ("AVN"), which provides comprehensive home health and hospice and palliative care services as well as adult day care services and various community health services, is also included within the Hospital. Each of the above operate as divisions within AHS Hospital Corp. and not as separate corporations. Also, included in the Hospital is the Foundation for the Morristown Medical Center ("MMCF"), a wholly owned subsidiary and not-for-profit fundraising organization. The Hospital is exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code.

The Hospital provides regional health care services including a broad range of adult, pediatric, obstetrical/gynecological, psychiatric, oncology, intensive care, cardiac care and newborn acute care services to patients from the counties of Morris, Essex, Passaic, Sussex, Bergen, Hunterdon, Union, Warren and Somerset in New Jersey, Pike County in Pennsylvania and southern Orange County in New York. The Hospital is also a regional health trauma center that provides tri-state coverage and provides numerous outpatient ambulatory services, rehabilitation and skilled care and emergency care.

Also included in the Hospital is Practice Associates Medical Group doing business as Atlantic Medical Group, P.A. ("AMG"), the captive physician practice serving all of the Hospital divisions. It is a nonprofit corporation and an organization described in Section 501(c)(3) of the Internal Revenue Code. Originally formed to provide billing and collection services for fees generated by physicians employed by the hospital divisions, AMG now serves as a physician-governed group practice entity with over 1,700 providers. AMG supports the Hospital by improving consistency, enhancing collaboration among those delivering care and optimizing care system operations.

MMCF solicits funds in its general appeal to primarily support the Morristown Division and the community as MMCF's Board may deem appropriate. The by-laws of MMCF were amended on November 19, 2015, to provide that funds received by MMCF after the date of the amendment may be used for the benefit of Atlantic Health System, Inc. (the "Parent") and the Hospital, including all subsidiaries, upon approval of the Executive Committee of the Board of MMCF.

In June 2019, Atlantic Rehabilitation Institute ("ARI") began operations under a joint venture between the Hospital and Kindred Healthcare ("Kindred"). ARI is a two-story, 38-bed rehabilitation facility, located in Madison, NJ and provides patient-focused rehabilitation dedicated to the treatment and recovery of individuals through intensive specialized rehabilitation services for patients who have experienced a loss of function from an injury or illness. The Hospital contributed the existing rehabilitation business for a 55% ownership investment. The Hospital consolidates the joint venture's operations and records an adjustment for the noncontrolling interest within other changes in net assets without donor restrictions on the consolidated statements of operations and separates Kindred's equity as noncontrolling interest within net assets without donor restrictions on the consolidated balance sheet.

(in thousands)

The Hospital is a wholly controlled subsidiary of the Parent, a not-for-profit organization. The Parent wholly owns the following for-profit entities; Atlantic Health Management Corp., a for-profit holding company, which owns AHS Investment Corporation and Subsidiaries ("AHSIC"); AHS Insurance Company, Ltd. (the "Captive"), a for-profit insurance company licensed under the provisions of the Cayman Islands Insurance Law; AHS Health Network LLC, a for-profit established to provide a vehicle to report risk contracting under the requirements of the banking and insurance regulations; Primary Care Partners, LLC, Atlantic Health Partners, LLC, and Atlantic Brain and Spine, LLC, for-profit physician practice entities; AHS ACO, LLC, Care Better ACO LLC and Premier Health ACO, LLC, for-profit limited liability companies established for the purpose of participating in the Medicare Shared Savings Program under the Patient Protection and Affordable and Accountable Care Act of 2010 as well as participating in shared savings programs with certain commercial carriers; and several urgent care and advanced urgent care centers located within the Hospital's geographic regions. AHSIC holds real estate interests and manages health care businesses including magnetic resonance imaging, durable medical equipment and private duty home care services. The Captive's principal activity is to provide for professional and commercial general liability insurance to the Parent and its subsidiaries beginning January 1, 2002. In addition, the Parent wholly owns the following not-for-profit entities: Atlantic Ambulance Corp., a not-forprofit company established to provide emergency and nonemergency medical transportation to the Parent and its subsidiaries; North Jersey Health Care Properties which owns commercial buildings; Prime Care, Inc. which provides various wellness, health education and other health services; and Newton Medical Center Foundation, Inc., and the Chilton Medical Center Foundation, Inc., both notfor-profit fund raising organizations for the benefit of their respective Hospital Divisions.

The Overlook Foundation and the Foundation for the Hackettstown Medical Center are not-forprofit fundraising organizations affiliated with the Overlook and Hackettstown Divisions, respectively, however, they are not controlled subsidiaries of the Parent or the Hospital.

Effective January 1, 2022, the Parent and CentraState Healthcare System ("CentraState"), a nonprofit health system with a continuum of care operating one acute care hospital in Freehold, New Jersey in Monmouth County, completed their newly expanded partnership, creating a unique model for health system co-ownership under which the Parent became the 51% majority corporate member in CentraState and CentraState joined the System's network of care. The partnership is structured to deliver benefits to patients, physicians, and caregivers in CentraState's communities by strengthening its integrated clinical services, physician network and infrastructure through capital investments. The transaction was accounted for by the Parent in accordance with ASC Topic 958-805, *Not-for-profit Entities: Business Combinations*. No consideration was exchanged to complete the partnership.

In January 2024, the Parent and Saint Peter's Healthcare System ("SPHS") signed a Letter of Intent ("LOI") to establish a strategic partnership, subsequently a Member Substitution Agreement on June 25, 2024. Under the terms of the Member Substitution Agreement, the Parent will become the sole member of SPHS. The new relationship will benefit both organizations and enhance healthcare services. Processes to obtain the required approvals from state and federal officials, and the Bishop of Diocese of Metuchen, currently the sole member of SPHS, are currently underway.

SPHS is a private, not-for-profit health system sponsored by the Roman Catholic Diocese of Metuchen. A major clinical affiliate of Rutgers Biomedical Health and Sciences, it includes Saint

(in thousands)

Peter's University Hospital in New Brunswick, ambulatory facilities, Saint Peter's Physician Associates, and a charitable foundation.

Under the terms of the Member Substitution Agreement, the Parent will invest in Saint Peter's University Hospital and the surrounding region, expanding service and access to greater Middlesex County. The two systems will work collaboratively to create significant synergies between the two organizations including transitioning SPHS onto the Parent's electronic medical record system. Additionally, SPHS will continue to carry on its Catholic mission and abide by the Ethical and Religious Directives for Catholic Health Care Services pursuant to a Catholic Identity Agreement to which the Parent will be a party.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements have been prepared on the accrual basis of accounting in conformity with accounting principles generally accepted in the United States of America ("GAAP"). The consolidated financial statements include the accounts of its controlled subsidiaries MMCF and AMG. All significant intercompany balances and transactions are eliminated in consolidation.

Adopted Authoritative Pronouncement

In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, *Financial Instruments – Credit Losses: Measurement of Credit Losses on Financial Instruments.* The previous standard delays the recognition of a credit loss on a financial asset until the loss is probable of occurring. The new standard removes the requirement that a credit loss be probable of occurring for it to be recognized, and requires entities to use historical experience, current conditions, and reasonable and supportable forecasts to estimate their future expected credit losses. The standard is required to be applied using the modified retrospective approach with a cumulative-effect adjustment to net assets, if any, upon adoption. This ASU is effective for the Hospital for fiscal years beginning after December 15, 2022. The Hospital has adopted this standard in 2023 and adoption did not have a material impact on the consolidated financial statements.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to contractual discounts for patient service revenue, third party payer settlements, self-insurance liabilities, investment valuation and accrued employee benefits. Actual results may differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents include highly liquid short-term investments with original maturities of three months or less from the date of acquisition. The Hospital elected to treat highly liquid short-term investments held within its assets limited as to use and long-term investments and other assets financial statement line items as investments, and therefore exclude them from cash and cash equivalents in the consolidated statements of cash flows.

(in thousands)

At December 31, 2024 and 2023, the Hospital had cash balances in a financial institution that exceeded federal depository insurance limits. Management believes that the credit risk related to these deposits is minimal.

Assets Limited as to Use and Investments

Assets limited as to use principally consist of short-term investments including money market funds held by a trustee under the bond indenture agreement and funds set aside by the Board of Trustees over which the Board of Trustees retains control and may, at its discretion, subsequently use for other purposes. Amounts required to meet current debt service payments of the Hospital have been classified as current in the consolidated balance sheets at December 31, 2024 and 2023.

Investments in equity securities with readily determinable fair values and all investments in debt securities are measured at fair value in the consolidated balance sheets. Investment income or loss, including realized gains and losses on investments, interest and dividends, and unrealized gains and loss, is included within nonoperating activities within the consolidated statements of operations, unless the income or loss is restricted by donor or law.

Beneficial Interest in Perpetual Trusts

The Hospital has been designated the beneficiary under certain perpetual trusts. The Hospital recognizes contribution revenue at the time an irrevocable trust is created at the fair value of the trust's assets. The contribution revenue is classified as net assets with donor restrictions. The Hospital revalues its interest in the perpetual trusts annually and reports any gain or loss as change in net unrealized gain (loss) from net asset with donor restrictions in the consolidated statement of changes in net assets. The underlying investments held in trust are held primarily in equity securities with readily determinable fair value. Income earned on the trust assets is included within nonoperating gains, net in the consolidated statements of operations.

Other Current Assets

Included within other current assets in the consolidated balance sheets are amounts due from related parties, prepaid expenses, and inventory.

Inventories

Inventories, primarily supplies, are included in other current assets and are stated at the lower of cost or net realizable value using the first-in, first-out method.

Property, Plant and Equipment

Property, plant and equipment are stated at cost. The Hospital provides for depreciation of land improvements, buildings and improvements, and equipment on a straight-line basis over the asset's estimated useful life. When assets are retired or otherwise disposed of, the cost and the related accumulated depreciation are reversed from the accounts, and any gain or loss is recorded in operations. Repairs and maintenance expenditures are expensed as incurred.

Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future net cash flows expected to be generated by the asset. If the carrying amount of the asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of

(in thousands)

the asset. For the years ended December 31, 2024 and 2023, there were no events that would indicate an impairment of long-lived assets.

Gifts of long-lived assets such as property, plant and equipment are recorded at the fair value at the date of the gift and reported as an increase to net assets without donor restrictions unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as contributions with donor restriction in the consolidated statements of changes in net assets. Absent explicit donor stipulations about how long those long-lived assets must be maintained, expirations of donor restrictions are reported when the donated or acquired long-lived assets are placed in service.

Leases

The Hospital leases certain office and distribution facilities ("real estate"), as well as medical and other equipment, which are all accounted for under FASB Accounting Standards Codification ("ASC") 842, *Leases*. The Hospital has made an accounting policy election to not apply recognition requirements of ASC 842 to short-term leases, which are those leases with a term of one year or less.

The Hospital considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether to renew or replace a real estate lease. Real estate agreements, which expire at various dates through 2040, often include renewal options, either at fixed rents or subject to a fair value assessment at the time of exercise. Real estate renewal options are included in the measurement of right of use asset and lease liabilities when the exercise of such options is reasonably certain. Equipment renewal options are excluded from the lease term because they are not reasonably certain to be renewed due to rapid technology changes.

There is generally no readily determinable discount rate implicit in the Hospital's leases. Accordingly, the Hospital uses its incremental borrowing rate throughout the terms of the lease, unless there is a modification, at which time, the rate may be updated with a more current incremental borrowing rate.

For real estate leases, the Hospital's accounting policy election is to separate lease and nonlease components. The Hospital includes the following as lease components when determining its real estate lease payments: fixed rent, predetermined rent escalations and rent-free periods. The Hospital recognizes rent expense on a straight-line basis over the related terms of such leases, beginning from when the Hospital takes possession of the asset. Variable rents resulting from adjustments to consumer price indices are recorded in the periods such amounts are adjusted and determined. Variable expenses are considered nonlease components and are expensed as incurred.

For equipment leases, the Hospital's accounting policy election is to not separate lease and nonlease components. Equipment lease agreements, including medical equipment, contain one fixed payment amount associated with the lease of the equipment, as well as maintenance, repairs, customer support, and training. Certain medical equipment leases also contain minimum purchases of consumables, which are considered in-substance fixed lease payments. The Hospital bundles its equipment lease payments. Lease expense is recognized on a straight-line basis over the related terms of such agreements.

(in thousands)

Net Assets

Net assets without donor restrictions are derived from gifts that are not subject to explicit donor-imposed restrictions. Resources arising from the results of operations or assets set aside by the Board of Trustees are classified as without donor restrictions for external reporting purposes.

Net assets with donor restrictions are those funds whose use by the Hospital has been limited by donors to a specific time period and/or purpose. Once the restrictions are satisfied, or have been deemed to have been satisfied, those assets with donor restrictions are released from restrictions. Certain donor restrictions are perpetual in nature and the income from those funds is expendable to support various healthcare services or projects. Net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions. Management of the Hospital has interpreted the State of New Jersey's enacted version of the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") as requiring the preservation of the historic dollar value of donor-restricted endowment funds (absent explicit donor stipulations to the contrary). Historic dollar value is defined as the aggregate fair value in dollars of (i) an endowment fund at the time it became an endowment, (ii) each subsequent donation to the fund at the time it is made, and (iii) each accumulation made pursuant to a direction in the applicable gift instrument at the time the accumulation is added to the fund. Based on this interpretation, the Hospital classifies as net assets with donor restrictions: (a) the original value of gifts donated to the restricted net assets, (b) the original value of subsequent gifts to the permanent endowment, (c) the net realizable value of future payments to restricted net assets in accordance with the donor's gift instrument (outstanding endowment pledges net of applicable discount), and (d) appreciation (depreciation), gains (losses) and income earned on the fund when the donor states that such increases or decreases are to be treated as changes in net assets with donor restrictions. The remaining portions of the donor-let restricted endowment fund that is not classified in net assets with donor restrictions in perpetuity is classified as net assets with donor restrictions until those amounts are appropriated for expenditure by the Hospital in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the Hospital considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund.
- (2) The purpose of the organization and the donor-restricted endowment fund.
- (3) General economic conditions.
- (4) The possible effect of inflation and deflation.
- (5) The expected total return from income and the appreciation of investments.
- (6) Other resources of the Hospital; and
- (7) The investment policies of the Hospital.

The Hospital has a policy of appropriating for distribution each year up to 5% of its endowment fund's average fair value over the prior 12 quarters through the calendar year end preceding the fiscal year in which the distribution is planned. In establishing this policy, the Hospital considered the long-term expected return on its endowment. This is consistent with the Hospital's objective to

(in thousands)

maintain the purchasing power of the endowment assets held in perpetuity or for a specified term as well as to provide additional real growth through new gifts and investment return. This method also compensates for any volatile year-to-year fluctuation in investment returns.

Management further understands that expenditures from a donor-restricted fund is limited to the uses and purposes for which the endowment fund is established and the use of net appreciation, realized gains (with respect to all assets) and unrealized gains (with respect only to readily marketable assets) is limited to the extent that the fair value of a donor-restricted fund exceeds the historic dollar value of the fund (unless the applicable gift instrument indicates that net appreciation shall not be expended), to the extent that such expenditure is prudent, considering the long and short term needs of the Hospital in carrying out its purposes, its present and anticipated financial requirements, expected total return on its investments and general economic conditions. Under the policies established and approved by the Hospital's Finance and Investment Committee, donor-restricted endowment funds are invested in income-generating investment vehicles to generate appreciation and preserve capital.

Unconditional promises to give cash and other assets are reported at fair value at the date the promise is received. The gifts are reported as net assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified as net assets without donor restrictions and reported in the consolidated statements of operations as net assets released from restrictions.

Net Patient Service Revenue and Patient Accounts Receivable

Net patient service revenue is reported at the amount that reflects the consideration to which the Hospital (including AMG and AVN) expects to be entitled in exchange for providing patient care. These amounts are net of appropriate discounts to give recognition to differences between the Hospital's charges and reimbursement rates from third party payers. The Hospital is reimbursed from third party payers under various methodologies based on the level of care provided. Physician services are billed at professional rates tied to contracts for visits and procedures done in the physician office setting. Certain net revenues received are subject to audit and retroactive adjustment for which amounts are accrued on an estimated basis in the period the related services are rendered and adjusted in future periods as final settlements are determined. The net amounts recorded, related to prior years and changes in estimates, increased (decreased) net patient service revenue by \$30,577 and (\$11,948) for the years ended December 31, 2024 and 2023, respectively.

Revenue is recognized as performance obligations are satisfied. The Hospital determines performance obligations based on the nature of the services provided. The Hospital recognizes revenues for performance obligations satisfied over time based on actual charges incurred in relation to total expected charges. Generally, performance obligations satisfied over time relate to patients in the Hospital receiving inpatient acute care services. The Hospital measures performance obligations from admission to the point when there are no further services required for the patient, which is generally the time of discharge. The Hospital recognizes revenues for performance obligations satisfied at a point in time, which generally relate to patients receiving outpatient services including physician practices, when: (1) services are provided; and (2) when there is no expectation that the patient requires additional services.

Because the Hospital's patient service performance obligations related to contracts with a duration of less than one year, the Hospital has elected to apply the optional exemption provided in FASB

(in thousands)

ASC 606, Revenue from Contracts with Customers and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Hospital determines the transaction price based on gross charges for services provided, reduced by the contractual adjustments provided to third party payers, discounts provided to uninsured patients in accordance with the Hospital's policy, and implicit price concessions provided to uninsured patients. The Hospital determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Hospital determines its estimate of implicit price concessions based on its historical collection experience with these classes of patients using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The consolidated financial statement effects of using this practical expedient are not materially different from an individual contract approach.

In general, patients who are covered by third party payers are responsible for related co-pays co-insurance and deductibles, which vary in amount. The Hospital also provides services to uninsured patients and offers uninsured patients a discount from standard charges. Then the Hospital estimates the transaction price for patients with co-pays, co-insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under the Hospital's uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual discount, which reduces net patient service revenue at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual discounts recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self-pay accounts and other factors that affect the estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenues in the period of the change.

A summary of the payment arrangements with major third-party payers is as follows:

Medicare

Inpatient acute care, behavioral care and rehabilitation services and most outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates per discharge. These rates vary according to a patient classification system that is based on clinical, diagnostic and other factors. The Hospital is reimbursed for certain reimbursable items at a tentative rate with final settlement determined after submission of the annual cost report by the Hospital and audits thereof by the Medicare administrative contractor. The Hospital's classification of patients under the Medicare program and the appropriateness of their admission are subject to an independent review by a peer review organization under contract with the Hospital. The Hospital's Medicare cost reports have been audited and finalized by the Medicare administrative contractor through December 31, 2021 for the Morristown, Newton, and Hackettstown Divisions, and 2020 for the Chilton and Overlook Divisions; however, the 2012 Medicare cost report for the Morristown Division remains open.

(in thousands)

Medicaid

Inpatient acute care services rendered to Medicaid program beneficiaries are paid at prospectively determined rates per discharge. These rates vary according to a patient classification system that is based on clinical, diagnostic and other factors. Outpatient services are paid based upon a cost reimbursement methodology and certain services are paid based on a Medicaid fee schedule. The Hospital is paid for reimbursable costs at a tentative rate with final settlement determined after submission of the annual cost report by the Hospital and audit thereof by the Medicaid fiscal intermediary. The Hospital's Medicaid cost reports have been audited and finalized by the Medicaid fiscal intermediary through December 31, 2022 for the Newton Division, and December 31, 2021 for the Morristown, Overlook, Chilton and Hackettstown Divisions.

Managed Care, Commercial and Other

The Hospital has also entered into payment agreements with certain commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for payment to the Hospital under these agreements includes prospectively determined rates per day/case and discounts from established charges.

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Noncompliance includes fines, penalties and exclusion from the Medicare and Medicaid programs. The Hospital has established a Corporate Compliance Program to monitor and maintain compliance with various regulations.

Other Revenue

Included within other revenue in the consolidated statements of operations are those amounts the Hospital derives from cafeteria sales, parking lot revenue, purchase discounts and various other miscellaneous receipts.

Performance Indicator

The consolidated statements of operations include excess (deficiency) of revenues over expenses as the performance indicator. Changes in net assets without donor restrictions which are excluded from excess (deficiency) of revenues over expenses, consistent with industry practice, include noncontrolling interest, equity transfers to related parties, changes in funded status of benefit plans, net assets released from restrictions for capital purposes, and government grants used for capital purchases. The Hospital differentiates its operating activities through the use of income from operations as an intermediate measure of operations. For the purposes of display, investment income, net, changes in unrealized gains (losses) on investments, and other nonoperating items (which include changes in the value of swap agreements and other components of net periodic benefit costs), which the Hospital does not consider to be a component of its operating activities are excluded from the income from operations in the consolidated statements of operations.

Fair Value

FASB ASC 820, Fair Value Measurements, establishes a framework for measuring fair value under GAAP and enhances disclosures about fair value measurements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value requires an organization to determine the unit of account, the mechanism of hypothetical transfer, and the appropriate markets for the asset or liability being measured.

(in thousands)

The guidance establishes a hierarchy of valuation inputs based on the extent to which the inputs are observable in the marketplace. Observable inputs reflect market data obtained from sources independent of the reporting entity and unobservable inputs reflect the entities own assumptions about how market participants would value an asset or liability based on the best information available. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value.

The following describes the hierarchy of inputs used to measure fair value and the primary valuation methodologies used by the Hospital for financial instruments measured at fair value on a recurring basis. The three levels of inputs are as follows:

- Level 1 Quoted market prices in active markets for identical assets or liabilities. Level 1 assets consist of short-term investments, including money market funds and common stock, as they are traded in an active market with sufficient volume and frequency of transactions.
- Level 2 Quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability. Level 2 assets consist of money market funds and mutual funds that are nonexchange traded and valued based on net asset values (NAV) calculated by the funds' independent administrators which are calculated at least daily. These valuations are readily observable in the marketplace or are supported by observable levels at which transactions are executed in the marketplace. As Level 2 investments include positions that are not traded in active markets and/or are subject to transfer restrictions, valuations may be adjusted to reflect illiquidity and /or no transferability, which are generally based on available market information. Redemptions from each of the funds can be made at least daily on the latest reported NAV.
- Level 3 Unobservable inputs for the asset or liability that are supported by little or no market activity and that are significant to the fair value. Level 3 assets consist of beneficial interests in perpetual trusts held by third parties, primarily invested in equities and fixed income securities.

For investments in alternative investments, fair value is measured based on unobservable inputs that cannot be corroborated by observable market data. The Hospital accounts for these investments within its long-term investment portfolio using the NAV as a practical expedient, and as such these investments are excluded from the fair value hierarchy.

Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:

Market Approach (M) - Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Cost Approach (C) - Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and

Income Approach (I) - Techniques to convert future amounts to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Inputs are used in applying the various valuation techniques and broadly refer to the assumptions the market participants use to make valuation decisions. Inputs may include price information, credit data, liquidity statistics and other factors. The Hospital utilized the best available information in measuring fair value (Notes 7 and 11).

3. Charity Care

The Hospital provides care to patients who meet certain criteria defined by the New Jersey Department of Health and Senior Services ("DOHSS") without charge or at amounts less than its established rates. The Hospital maintains records to identify and monitor the level of charity care it provides. These records include the amount of charges foregone for services and supplies furnished. The Hospital receives partial reimbursement for the uncompensated care it provides Note 4). The estimated amount of charity care provided at cost under DOHSS guidelines during the years ended December 31, 2024 and 2023 amounted to approximately \$140,318 and \$114,481, respectively.

The estimated charity care cost is based on the calculation of a ratio of cost to gross charges, and then multiplying that ratio by the gross charges foregone for providing charity care (i.e. charity care discounts).

4. Net Patient Service Revenue

The components of net patient service revenue for the Hospital (including AVN and AMG) for the years ended December 31, 2024 and 2023 are as follows:

	2024	2023
Gross charges		
Inpatient	\$ 9,621,267	\$ 8,666,258
Outpatient	10,069,440	8,736,554
Physician practices	1,563,778	1,399,513
Total gross charges	21,254,485	18,802,325
Net additions (deductions) from gross charges		
Contractual discounts and implicit price concessions	(16,791,535)	(14,761,434)
Charity care discount	(172,351)	(140,280)
Subsidies from State of New Jersey	17,782	13,295
	(16,946,104)	(14,888,419)
Net patient service revenue	\$ 4,308,381	\$ 3,913,906

The Hospital recorded \$159,733 and \$102,353 of implicit price concessions as a direct reduction of patient service revenues during the years ended December 31, 2024 and 2023, respectively.

The mix of Hospital net patient service revenue (excluding net revenue recorded by AMG), net of contractual discounts and implicit price concessions by payer for the years ended December 31, 2024 and 2023 is as follows:

	2024	2023
Medicare	24.4 %	23.3 %
Medicaid	1.0	1.0
Managed care and other third party payers	73.1	75.4
Self pay	1.0	0.1
State Subsidies	0.5	0.2
	100.0 %	100.0 %

Net patient service revenue recorded by AMG's physician practices amounted to \$566,467 and \$514,249 for the years ended December 31, 2024 and 2023, respectively. AMG's net patient service revenue by payer for the years ended December 31, 2024 and 2023, is as follows:

	2024	2023
Medicare	22.7 %	22.7 %
Medicaid	0.4	0.3
Managed care and other third party payers	76.7	76.8
Self pay	0.2	0.2
	100.0 %	100.0 %

5. Federal Legislative Relief Funds

Congress has appropriated funds to reimburse eligible health care providers for healthcare expenses incurred and/or loss in revenue due to COVID-19.

During 2024 and 2023, the Hospital applied for and received approval from FEMA for the reimbursement of qualifying capital and noncapital COVID-19 related expenses. The Hospital recognized \$872 and \$29,424 within operating revenue in the consolidated statements of operations for the years ended December 31, 2024 and 2023, respectively. In addition, during the year ended December 31, 2023, the Hospital recognized \$22,250 within government grants used for capital purposes in the consolidated statement of operations. No such funding for capital purposes was received in 2024. FEMA can and does retrospectively adjust grant distribution formulas and may adjust funding already received which may impact the amount the Hospital has recorded for the years ended December 31, 2024 and 2023 in future financial statement periods.

6. Concentration of Credit Risk

The Hospital extends credit without collateral to its patients, most of whom are local residents and are insured under third-party payer agreements. Accounts receivable net of contractual discounts and implicit price concessions from patients and third-party payers, as of December 31, 2024 and 2023, were as follows:

	2024	2023
Medicare	17.2 %	19.1 %
Medicaid	2.5	2.2
Managed care and other third party payers	71.4	69.1
Self pay	8.9	9.6
	100.0 %	100.0 %

7. Assets Limited as to Use, Long-Term Investments and Other Assets

Assets limited as to use at December 31, 2024 and 2023 consist of the following:

	2024		2023
Board designated for capital and program costs			
Short-term investments including money market funds	\$ 254,899	\$	287,566
Equity securities	416,132		381,183
Fixed income funds	648,941		540,640
Mutual funds	1,542,043		1,438,758
Alternative investments - equity	 28		127
	 2,862,043		2,648,274
Under bond indenture agreements			
Short-term investments including money market funds			
Interest account	3,167		3,499
Principal account	6,949		6,602
Debt service reserve fund	671	_	672
	 10,787		10,773
Total assets whose use is limited	2,872,830		2,659,047
Less: Assets limited as to use and are			
required for current liabilities	 67,872		68,070
Noncurrent assets limited as to use	\$ 2,804,958	\$	2,590,977

Assets limited as to use under bond indenture agreements represent certain funds that are controlled by trustees for as long as any of the bonds remain outstanding. These funds, including interest income, are held by bank trustees who administer the trusts as required under the bond indenture agreements.

Long-term investments and other assets, at December 31, 2024 and 2023, are as follows:

	2024	2023
Long-term investments		
Short term investments including money market funds	\$ 4,703	\$ 3,128
Mutual funds	82,423	79,713
Alternative investments - equity	 7,946	 3,497
	95,072	86,338
Other assets		
AHSIC intercompany loans	112,200	117,147
Professional and general liability insurance recoveries	118,516	111,971
CentraState intercompany loans	113,816	113,497
Workers compensation liability insurance recoveries	8,300	7,200
Accrued employee benefit asset (Note 11)	37,841	-
Due from Overlook Foundation	40,481	42,864
Due from Newton Medical Center Foundation	3,385	3,897
Due from Chilton Medical Center Foundation	6,407	6,102
Due from the Foundation for Hackettstown Medical Center	2,328	2,242
Venture capital private equity funds	24,253	25,447
Equity method investments	3,842	3,712
Beneficial interest in trusts	2,634	2,209
Goodwill	14,633	-
Life interest in real estate	9,000	-
Other	8,918	9,751
	 506,554	 446,039
Total long-term investments and other assets	\$ 601,626	\$ 532,377

On August 17, 2022, the Hospital entered into a secured loan agreement with CentraState in the amount of \$103,497, whereby the proceeds were utilized by CentraState to pay off or legally defease all of its financed obligations as of that date. CentraState will pay interest to the Hospital monthly at a fixed rate of 3.21% with the full principal amount due to the Hospital on May 17, 2037. The loan is collateralized by the gross receipts of CentraState as well as its owned properties. In addition, certain financial covenants must be maintained by CentraState. On July 1, 2024, CentraState sold the Center for Aging, Inc. d/b/a Applewood, its wholly owned subsidiary to an unrelated entity. Upon sale, CentraState transferred \$19,681 to the Hospital to pay off the portion of the secured loan related to Applewood.

On August 31, 2023, the Hospital entered into a revolving credit loan agreement with CentraState in the amount of \$30,000, whereby drawdowns were utilized by CentraState to pay working capital requirements to meet its obligations. CentraState will pay interest to the Hospital monthly at a fixed annual rate of 5% with the full principal amount due to the Hospital on August 31, 2028. At December 31, 2024 and 2023, CentraState had drawn down \$30,000 and \$10,000 on the revolving credit loan.

The Hospital accrues an estimate of the ultimate cost of claims under all insurance policies whether the policy is fully insured or a self-insurance policy, with any insurance recoverable under such

(in thousands)

policies recorded as a receivable. As of December 31, 2024 and 2023, the Hospital has recorded a corresponding liability for professional and general liability insurance claims within accounts payable and accrued expenses in the consolidated balance sheets (Note 12). As of December 31, 2024 and 2023, the Hospital recorded liabilities related to estimated gross workers compensation claims totaling \$26,300 and \$22,700, respectively, within accounts payable and accrued expenses in the consolidated balance sheets.

Due from Overlook, Newton, Chilton and Hackettstown Medical Center Foundations relate to the amounts due from the Foundations for contributions received by the Foundations on behalf of the Overlook, Newton, Chilton and Hackettstown Divisions. The Foundations solicit funds in their general appeal to support the Hospital and for other health care purposes as the respective Foundation's individual Board of Trustees may deem appropriate. In the absence of donor restrictions, the Foundations' have discretionary control over the amounts to be distributed to the providers of health care services, the timing of such distributions, and the purposes for which such funds are used. The assets held at the affiliated foundations are comprised primarily of cash and cash equivalents, marketable equity securities and debt securities.

Investment income relating to long-term investments and assets limited as to use, excluding those held under bond indenture agreements and restricted funds, for the years ended December 31, 2024 and 2023 consist of the following:

	2024	2023
Interest and dividend income Realized gains (losses) on sales of securities	\$ 79,172 71,230	\$ 69,433 (9,039)
Investment income	150,402	60,394
Change in net unrealized gains (losses)	 69,325	 289,748
Total investment return	\$ 219,727	\$ 350,142

(in thousands)

The fair value of the Hospital's financial assets that are measured on a recurring basis at December 31, 2024 and 2023 are as follows:

	i Ma	oted Prices in Active arkets for Identical Assets	Significant Other Observable Inputs	Unc	gnificant bbservable Inputs	-	Fair Value	Valuation
2024	((Level 1)	(Level 2)	(Level 3)		2024	Technique ⁽¹⁾
Assets limited as to use Short-term investments including money market funds Equity securities Fixed income funds Mutual funds	\$	265,686 416,132 - - 681,818	 648,941 1,542,043		- - - -	\$	265,686 416,132 648,941 1,542,043	M M M
	Ф	001,010	\$ 2,190,984	Ф	-	Ф	2,872,802	
Investments measured at net asset value						\$	28 2,872,830	
Long-term investments Short-term investments including								
money market funds Mutual funds	\$	4,703 <u>-</u>	\$ - 82,423	\$	<u>-</u>	\$	4,703 82,423	M M
	\$	4,703	\$ 82,423	\$		\$	87,126	
Investments measured at net asset value							7,946	
						\$	95,072	
Life interest in real estate Beneficial interests in	\$		\$ 	\$	9,000	\$	9,000	М
perpetual and remainder trusts	\$		\$ 	\$	2,634	\$	2,634	М
Venture capital private equity funds	\$		\$ <u>-</u>	\$	24,253	\$	24,253	М

(in thousands)

2023	ii Ma	oted Prices in Active arkets for dentical Assets Level 1)		Significant Other Observable Inputs (Level 2)	Uno	gnificant bservable Inputs ∟evel 3)	-	air Value cember 31, 2023	Valuation Technique ⁽¹⁾
Assets limited as to use									
Short-term investments including									
money market funds	\$	298,339		-		-	\$	298,339	М
Equity securities		381,183		-		-		381,183	M
Fixed income funds		-		540,640		-		540,640	M
Mutual funds		-	_	1,438,758				1,438,758	М
	\$	679,522	\$	1,979,398	\$		\$	2,658,920	
Investments measured at net asset value								127	
							\$	2,659,047	
Long-term investments									
Short-term investments including									
money market funds	\$	3,128	\$	-	\$	-	\$	3,128	M
Mutual funds				79,713				79,713	М
	\$	3,128	\$	79,713	\$		\$	82,841	
Investments measured at net asset value								3,497	
							\$	86,338	
Beneficial interests in									
perpetual and remainder trusts	\$		\$		\$	2,209	\$	2,209	M
Venture capital private equity funds	\$		\$		\$	25,447	\$	25,447	М

⁽¹⁾ The three valuation techniques are market approach (M), cost approach (C), and income approach (I), as discussed in Note 2.

There was no significant Level 3 investment activity for the years ended December 31, 2024 and 2023.

8. Property, Plant and Equipment

Property, plant and equipment at December 31, 2024 and 2023 are as follows:

	2024	2023	Depreciable Life (in Years)
Land Buildings and improvements	\$ 74,772 1,949,739	\$ 74,772 1,865,268	10–50
Equipment and fixed equipment Construction in progress	1,906,178 230,657	1,797,208 114,826	3–25
· ·	4,161,346	 3,852,074	
Less: Accumulated depreciation	2,626,442	2,445,398	
Property, plant and equipment, net	\$ 1,534,904	\$ 1,406,676	

Depreciation and amortization expense for the years ended December 31, 2024 and 2023 was \$183,188 and \$178,965, respectively.

(in thousands)

9. Long-Term Debt

Long-term debt at December 31, 2024 and 2023 consists of the following:

		2024	2023
\$100,000 JP Morgan Chase Taxable Term Loan maturing on May 31, 2037. Principal is payable quarterly as is interest at an annual interest rate of 3.21%. The loan is collateralized by the Hospital's gross receipts.	\$	91,667	\$ 95,000
\$450,000 Series 2021 Taxable Bonds (Fixed Rate) maturing on July 1, 2051. Interest is payable each January 1 and July 1 at an annual interest rate of 2.78%. The bonds are collateralized by the Hospital's gross receipts.		450,000	450,000
\$224,800 New Jersey Health Care Facilities Financing Authority ("NJHCFFA"), AHS Hospital Corporation, Series 2016 Refunding Bonds (Fixed Rate), in varying maturities through 2041 at annual interest rates varying between 3.00% and 5.00%. Interest is payable each January 1 and July 1 and principal is payable each July 1 commencing in 2017. As of December 31, 2024, the average interest rate on the bonds was 4.21%. The bonds are collateralized			
by the Hospital's gross receipts.		146,925	159,170
\$425,000 Series 2015 Taxable Bonds (Fixed Rate) maturing on July 1, 2045. Interest is payable each January 1 and July 1 at an annual interest rate of 5.02%. The bonds are collateralized by		405.000	405.000
the Hospital's gross receipts.		425,000	425,000
\$50,000 Bank of America Taxable Term Loan maturing on December 1, 2028. Interest is payable monthly at an annual interest rate of 5.60%. The loan is collateralized by the Hospital's gross receipts.		50,000	50,000
\$177,110 NJHCFFA AHS Hospital Corporation, Series 2008A Revenue Bonds (Fixed Rate), in varying maturities through 2027 at annual interest rates varying between 4.88% and 5.00%. Interest is payable each January 1 and July 1 and principal is payable each July 1 commencing in 2009. As of December 31, 2024, the average interest rate on the bonds was 5.00%. The bonds are collateralized by the Hospital's gross receipts. \$177,110 NJHCFFA AHS Hospital Corporation, Series 2008B and 2008C Revenue Bonds (Variable Rate), in varying maturities commencing in 2027 through 2036 at annual interest rate of 3.08%. The interest on the bonds is payable monthly and principal will be payable each July 1. As of December, 31, 2024, the average		1,515	2,070
interest rate on the bonds was 3.40%. The bonds are			
collateralized by the Hospital's gross receipts.	-	177,110	 177,110
Total long-term debt		1,342,217	1,358,350
Unamortized bond premium Deferred financing fees		49,219 (5,403)	51,824 (5,655)
Deferred financing fees		1,386,033	 (5,655) 1,404,519
Less: Current portion of long-term debt		19,136	18,486
Long-term debt, net of unamortized bond premium,		10,100	 10,100
debt issuance costs, and current portion	\$	1,366,897	\$ 1,386,033

(in thousands)

The Hospital is the sole member of the obligated group as defined in and established under the Master Trust Indenture. Neither the Parent nor any of its affiliates is liable to make any payment with respect to the bonds or any other obligations under the Master Indentures. Under the terms of the Master Trust Indenture, the Hospital is required to maintain certain deposits with a trustee, which are included with assets limited as to use in the consolidated balance sheets. The Master Trust Indenture also contain provisions whereby certain financial ratios are to be maintained and permit additional borrowings subject to the maintenance of specific financial ratios. The most restrictive covenant is for the Hospital to maintain a debt service coverage ratio in each year of at least 1.2 times the debt service requirement on all long-term debt in that year. The Hospital is compliant with its financial covenants at December 31, 2024 and 2023.

On May 31, 2022, the Hospital entered into a \$100,000 taxable loan agreement with a commercial bank. The loan proceeds are to be used for general corporate purposes. Principal and interest, at a fixed rate of 3.21% on the outstanding balance, are due quarterly commencing September 1, 2022, with the remaining unpaid principal in the amount of approximately \$50,833 due and payable on May 31, 2037. The agreement contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants. Subsequently, the Hospital entered into a secured loan agreement with CentraState to enable CentraState to pay off or legally defease all if its financed obligations as of that date (Note 7).

On January 27, 2021, the Hospital issued \$450,000 Series 2021 Fixed Rate Taxable Bonds, the proceeds of which will be used for eligible corporate purposes of the Hospital and its affiliates. In addition, a portion of the proceeds were used to pay the costs of issuance. The Hospital also utilized the proceeds of the bonds to repay \$50,000 that was outstanding on its \$200,000 revolving line of credit. The agreement contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants.

On April 21, 2020, the Hospital entered into a \$200,000 revolving credit agreement with a commercial bank to provide for additional liquidity. The line was set to expire on April 19, 2025. The line incurs interest at a rate of SOFR adjusted by 0.75% per annum on the amount drawn. Additionally, the line incurs a monthly fee of 0.15% on the unused portion of the line of credit. There were no amounts drawn on the line as of either December 31, 2024 or 2023. However, the Hospital drew down \$200,000 on April 4, 2024 which was fully repaid by October 30, 2024. The line of credit contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants. On April 1, 2025, the Hospital renewed the line for an additional year, with an interest at a rate of SOFR adjusted by 0.70% per annum on the amount drawn down and a monthly fee of 0.125% on the unused portion of the line of credit.

In October 2016, the Hospital issued \$224,800 Series 2016 Fixed Rate Tax-exempt Revenue Bonds through the NJHCFFA. The proceeds were used to refund a portion of the principal of its outstanding Revenue Bonds issued through the NJHCFFA in the amount of \$114,255 (Series 2008A) and \$120,115 (Series 2011), and to pay all of the cost of issuance in the amount of \$1,782. In addition, the NJHCFFA released \$14,260 of the Hospital's debt service reserve fund in connection with the bond refunding to pay down a portion of the aforementioned outstanding principal on the Series' 2008A and 2011 bonds.

(in thousands)

In May 2015, the Hospital issued \$200,000 Series 2015 Fixed Rate Taxable Bonds, the proceeds of which are to be used for eligible corporate purposes of the Hospital and its affiliates. In addition, a portion of the proceeds were used to pay the costs of issuance. Effective August 2017, the Hospital executed a "tap" on the Series 2015 Fixed Rate Taxable Issuance for an additional \$225,000. The Hospital received total proceeds of \$268,023, which included a premium of \$43,023. The agreement contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants.

In December 2013, the Hospital entered into a \$50,000 taxable loan agreement with a commercial bank. The majority of the proceeds were used to legally defease Chilton Division's NJHCFFA Series 2009 Revenue Bonds, which were assumed by the Hospital in 2014, concurrent with the merger. The agreement contains provisions whereby certain financial ratios are to be maintained which mirror those of the Hospital's outstanding tax-exempt bond covenants.

In May 2008, the Hospital issued, through the NJHCFFA, \$177,110 Series 2008A Revenue Bonds (Fixed Rate) and \$177,110 Series 2008B and 2008C Revenue Bonds (Variable Rate), collectively referred to as the 2008 Bonds, to pay in full the Hospital's obligations under the interim method of financing enabling the Hospital to redeem all of its outstanding bond issues and terminate a portion of its related swaps for the Series 2003, 2004, 2006 and 2007 Revenue Bonds. The proceeds of the 2008 Bonds were also used to pay the costs of issuance of the 2008 Bonds. The Series 2006 and Series 2007 Revenue Bonds were issued in part to pay for the costs of certain capital projects of the Hospital and construction trustee funds were set up for disbursement for the payment of such costs. Amounts equal to the amounts on deposit in such construction funds were deposited with the trustee for the 2008 proceeds to complete those projects. In connection with the issuance of the Series 2016 Refunding Bonds noted above, \$114,255 of the outstanding principal was refunded in October 2016.

The 2008 Variable Rate Bonds bear interest at weekly rates as determined by the remarketing agent. In the event that the purchase price of the corresponding Series of the Variable Bonds are not remarketed at the corresponding principal amount of such Series, the Variable Bonds are backed by a separate, irrevocable direct pay letters of credit by two banks, each expiring January 2026.

The future principal payments on long-term debt are as follows:

2025	\$ 16,783
2026	188,243
2027	6,038
2028	55,668
2029	5,468
Thereafter	 1,070,017
	\$ 1,342,217

(in thousands)

Interest Swaps

On April 9, 2008, the Hospital unwound and reissued two new barrier swaps: the 2008 Swap and the 2004 Swap.

The 2008 Swap was reissued in place of the 2006A Swap when the Series 2006A Revenue Bonds were redeemed. This was a noncash transaction. The original notional amount of the swap was \$91,550 subject to reduction in the principal amortization of a portion of the Hospital's Series 2008 variable rate debt and will expire on July 1, 2036, with an annual fee of 0.51%. The notional amount of the swap was \$87,400 at December 31, 2024 and 2023. Under the terms of the swap agreement, if the Securities Industry and Financial Markets Association ("SIFMA"), formerly known as the Bond Market Association, Municipal Swap Index, exceeds 4.05% for 90 days, the Hospital will pay a fixed rate of 4.00% in addition to the annual fee of 0.51%. The Hospital will then receive 68% of SOFR and pay the counterparty 4.00%. Currently the swap is treated as an ineffective swap for accounting purposes until SIFMA exceeds 4.05% for 90 days, at that time the swap will be tested to determine if it qualifies as a cash flow hedge.

The 2004 Swap was reissued in place of the original 2004 Swap when the Series 2003 and 2004 Revenue Bonds were redeemed. This was a noncash transaction and there were no changes to the terms of the swap. The notional amount of the swap was \$97,525, subject to reduction in the principal amortization of a portion of the Hospital's Series 2008 variable rate debt and will expire on July 1, 2025, with an annual fee of 0.52%. The notional amount of the swap at December 31, 2024 and 2023 was \$5,175 and \$10,025, respectively. Under the terms of the swap agreement, if SIFMA exceeds 4.05% for 90 days, the Hospital will pay a fixed rate of 4.00% in addition to the annual fee of 0.52%. The Hospital will then receive 68% of SOFR and pay the counterparty 4.00%. Currently the swap is treated as an ineffective swap for accounting purposes until SIFMA exceeds 4.05% for 90 days, at that time the swap will be tested to determine if it qualifies as a cash flow hedge.

The following table presents the swap liabilities, recorded in accrued employee benefits and other, net of current portion, as of December 31, 2024 and 2023:

	2024			2023		
2008 interest rate swap	\$	4,232	\$	5,763		
2004 interest rate swap		16		58		

(in thousands)

The following table sets forth the effect of the interest rate swap agreements on the consolidated statements of operations for the years ended December 31, 2024 and 2023:

	Amount of Gain (Los Recognized in the Performance Indicat			the	
		2024	2023		
Derivative in nonhedging relationship					
Nonoperating gains (loss), net					
2008 interest rate swap	\$	1,531	\$	1,477	
2004 interest rate swap		42		67	

In accordance with the above swap agreements, the Hospital is required to fund a cash collateral account if the market value of the combined swaps exceeds the trigger amount of \$12,000. As of December 31, 2024 and 2023, the combined market value of the swaps was below the trigger and as such, no collateral was required by the counterparty.

10. Leases

Lease expense recognized within supplies and other expenses in the consolidated statements of operations for the years ended December 31, 2024 and 2023 are as follows:

	2024	2023		
Fixed operating lease expense Short-term lease expense Sublease income	\$ 55,505 6,721 (2,924)	\$ 50,458 5,662 (3,597)		
Net lease expense	\$ 59,302	\$ 52,523		

The weighted average lease terms and discount rates for the Hospital's operating leases for the years ended December 31, 2024 and 2023 are as follows:

	2024	2023
Weighted average remaining lease term (in years)		
Real estate leases	9.2	9.9
Equipment leases	3.5	2.2
Weighted average discount rate for operating leases	4.48 %	4.13 %

The following table provides supplemental cash flow information related to the Hospital's operating leases for the years ended December 31, 2024 and 2023:

	2024	2023
Cash paid for amounts included in the measurement of lease liabilities operating cash flows for operating leases Right of use assets obtained in exchange for operating	\$ 61,156	\$ 55,737
lease liabilities	99,646	16,192

The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter to the operating lease liability recorded on the consolidated balance sheet for operating leases existing as of December 31, 2024:

2025	\$ 62,923
2026	58,102
2027	51,024
2028	43,209
2029	39,959
Thereafter	159,921
Total minimum lease commitments	415,138
Less: Imputed interest	 57,561
Present value of lease liabilities	357,577
Less: Current portion of lease liabilities	 49,576
Long-term lease liabilities	\$ 308,001

Minimum lease commitments after 2029 include \$22,164 associated with renewal options that are reasonably certain to be exercised. Refer also to Note 13 for lease arrangements with related parties, which are included above.

11. Pension and Other Postretirement Benefit Plans

Defined Benefit Plans

The Hospital maintains a defined benefit cash balance pension plan ("Cash Balance Plan") covering substantially all full-time employees, as well as various supplemental retirement plans, which provide pension benefits to certain key executives. Effective January 1, 2014, the Cash Balance Plan was frozen to new employees hired after December 31, 2013.

The Chilton Division had a noncontributory defined benefit retirement plan ("Chilton Plan") covering substantially all of its full-time employees. Effective June 20, 2012, the Chilton Plan was frozen to all future benefits while preserving all benefits that had accrued as of June 30, 2012. Chilton Division was required to fund the Chilton Plan for benefit obligations. As of December 31, 2014, the Chilton Plan merged its assets and liabilities with the Cash Balance Plan. The Hospital's funding policy provides that payments to the Cash Balance Plan shall at least be equal to the

(in thousands)

minimum funding requirement of the Employee Retirement Income Security Act of 1974 ("ERISA") plus additional amounts, which may be approved by the Hospital from time to time.

The Hospital sponsors three defined benefit postretirement plans at the Morristown and Overlook Divisions and formerly owned General Hospital Center at Passaic (the "General"). A description of the individual site plans are as follows:

- The Morristown Division plan pays the cost of providing medical and life insurance
 postretirement benefits to employees and qualifying dependents (spouse or child) of the
 Hospital who retire under the retirement plan and meet the specified age and service
 requirements. Contributions were introduced beginning in 2003 for all current and future
 retirees.
- The Overlook Division plan provides postretirement medical benefits to eligible employees and their qualifying dependents (spouse or child). The benefits for services provided outside the Hospital are subject to deductibles and co-payments. There is no charge for services provided in the Hospital except for prescription drugs, which are charged at cost. In addition, the Hospital provides postretirement life insurance coverage for employees hired prior to July 2, 1995.
- The General plan provides for life insurance and medical benefits for certain employees retired as of July 1996, at which time the plan was amended to exclude all active employees who had not retired as of that date.

Both the Morristown Division and Overlook Division postretirement plans were amended in May 1996 to exclude new employees from participation.

(in thousands)

The following tables provide a reconciliation of the changes in the plans' benefit obligation and fair value of assets for the years ended December 31, 2024 and 2023, a statement of the funded status of the plans and, the amounts recognized in the consolidated balance sheets as of December 31, 2024 and 2023.

	Pension Benefits			Other Postretirement Benefits				
		2024		2023		2024		2023
Accumulated benefit obligation	\$	875,137	\$	892,329	\$	131,023	\$	161,095
Change in benefit obligation								
Benefit obligation at beginning of year	\$	921,650	\$	859,439	\$	134,597	\$	131,023
Service cost		34,950		32,173		210		262
Interest cost		47,023		45,792		7,003		7,048
Plan participants' contributions		=		-		647		622
Actuarial (gain) loss		(35,561)		45,139		(2,366)		2,760
Plan amendments		-		(3,886)		-		-
Settlements		-		(43)		-		-
Benefits paid		(62,111)		(56,964)		(7,187)		(7,118)
Benefit obligation at end of year		905,951		921,650		132,904		134,597
Change in plan assets								
Fair value of plan assets at beginning of year		924,327		804,664		86,247		78,390
Actual return on plan assets		21,576		108,175		4,683		13,911
Medicare Part D subsidy		-		-		200		189
Employer contributions		60,000		68,452		211		253
Plan participants' contributions		-		-		647		622
Benefits paid		(62,111)		(56,964)		(7,187)		(7,118)
Fair value of plan assets at end of year		943,792		924,327		84,801		86,247
Funded status	\$	37,841	\$	2,677	\$	(48, 103)	\$	(48,350)
Amounts recognized in the consolidated balance sheets consist of								
Current liabilities	\$	-	\$	-	\$	(1,103)	\$	(1,179)
Long-term assets (liabilities)		37,841		2,677		(47,000)		(47,171)
Accrued employee benefit asset (liabilities)	\$	37,841	\$	2,677	\$	(48, 103)	\$	(48,350)
Amounts recognized in net assets without donor restrictions consist of								
Actuarial net loss	\$	219,402	\$	233,998	\$	4,675	\$	5,738
Prior service cost		1,332	<u> </u>	1,691	<u> </u>		Ψ	-
	\$	220,734	\$	235,689	\$	4,675	\$	5,738

The Cash Balance Plan discount rate increased by 60 basis points in the current year and decreased by 24 basis points in the prior year, resulting in an approximate \$44,400 gain and (\$18,100) loss in 2024 and 2023, respectively.

The following tables provide the components of the net periodic pension and other postretirement benefit costs and the total amount recognized in net periodic benefit cost and changes in net assets without donor restrictions for the years ended December 31, 2024 and 2023:

				Other Pos	retir	ement	
	Pension Benefits			Benefits			
	2024		2023	2024		2023	
Net periodic benefit cost							
Service cost	\$ 34,950	\$	32,173	\$ 210	\$	262	
Interest cost	47,023		45,792	7,003		7,048	
Expected return on plan assets	(56,826)		(51,499)	(5,197)		(4,673)	
Settlement (credit) charge	-		(43)	· -		-	
Actuarial loss (gain)	14,285		17,581	(804)		(664)	
Amortization of prior service cost	 359		359	<u> </u>		<u> </u>	
Net periodic benefit cost	39,791		44,363	1,212		1,973	
Amounts recognized in changes in net assets without donor restrictions							
Net gain	(14,955)		(29,118)	(1,063)		(5,835)	
Prior service cost	-		(359)	· -		· -	
	(14,955)		(29,477)	(1,063)		(5,835)	
Total recognized in net periodic benefit cost and change in net assets without							
donor restrictions	\$ 24,836	\$	14,886	\$ 149	\$	(3,862)	

The Hospital recorded the nonservice cost components of the net periodic benefit costs for its pension and postretirement benefit plans of \$5,843 and \$13,901 within nonoperating gains, net in the consolidated statements of operations for the years ended December 31, 2024 and 2023, respectively.

Assumptions used in determining the benefit obligations and net periodic benefit cost are as follows:

			Other Postre	tirement	
	Pension Be	enefits	Benefits		
	2024	2023	2024	2023	
Benefit obligations					
Discount rate	5.98 %	5.38 %	6.16 %	5.57 %	
Rate of compensation increase	4.00	4.00	4.00	4.00	
Net periodic benefit cost					
Discount rate	5.38 %	5.62 %	5.57 %	5.77 %	
Expected return on plan assets	6.25	6.50	6.25	6.20	
Rate of compensation increase	4.00	3.00	4.00	3.00	

The postretirement plans assumed an annual rate of increase in the per capita cost of covered health care benefits of 7.75% for the years ended December 31, 2024 and 2023. The rate was assumed to decrease gradually to 4.04% for 2075 and remain at that level thereafter.

The Cash Balance Plan's weighted average interest crediting rate assumption is 6.32% and 4.22% for all account balances for 2024 and 2023, respectively.

Expected Benefit Payments

The benefits expected to be paid in each year from 2025 to 2034 are:

				tretirement efits		
	Pension Benefits		lithout edicare ubsidy	With Medicare Subsidy		
2025	\$ 102,811	\$	8,189	\$	7,757	
2026	67,022		7,954		7,480	
2027	68,464		8,575		8,059	
2028	72,486		9,178		8,621	
2029	74,175		9,737		9,141	
2030-2034	399,258		54,933		51,482	

The aggregate benefits expected to be paid are based on the same assumptions used to measure the benefit obligation at December 31, 2024 and include estimated future employee service.

Plan Assets

The Hospital considers multiple factors in establishing its multi-year expected return on plan assets assumption. These include but are not limited to its current asset allocation policy and target ranges by asset class; asset valuations; historical and projected rates of return by asset class; historical and projected correlations among asset classes; the opportunity to exceed passive index returns via active management through a combination of manager selection and alternative weightings among and within asset classes and the Hospital's historical performance experience.

The Hospital's investment objective is to achieve the highest reasonable total return after considering (i) plan liabilities, (ii) funding status and projected cash flows, (iii) projected market returns, valuations and correlations for various asset classes, and (iv) the Hospital's ability and willingness to incur market risk. The Hospital actively manages plan assets in order to add incremental returns by manager selection and asset allocation (increasing/decreasing allocations within allowable ranges based on current and projected valuations).

The Plans' weighted average asset allocations are as follows:

	Percentage of Plan Assets									
	Р	ension Benefits		Other P	ostretirement Ber	nefits				
	Target			Target						
Asset Category	Allocation	2024	2023	Allocation	2024	2023				
Equity securities	35-85%	23 %	29 %	55-80%	71 %	70 %				
Debt securities	20-50%	27	26	10-30%	25	26				
Other	0-25%	50	45	0-10%	4	4				
		100 %	100 %		100 %	100 %				

(in thousands)

The following tables summarize the Cash Balance Plan's financial instruments, which are measured at fair value on a recurring basis by caption and by level within the valuation hierarchy as of December 31, 2024 and 2023:

2024	Markets for Identical Ol Assets		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Fair Value December 31, 2023		Valuation Technique ⁽¹⁾	
Plan assets Money market funds Mutual funds Fixed income funds Investments measured at net asset value	\$	8,981 - - 8,981	\$	217,657 254,283 471,940	\$	- - - -	\$	8,981 217,657 254,283 480,921 462,871 943,792	M M M	
2023	in Ma Id	ted Prices Active rkets for lentical Assets Level 1)	OI	ignificant Other bservable Inputs Level 2)	Signif Unobse Inpi (Leve	rvable ıts		air Value cember 31, 2023	Valuation Technique ⁽¹⁾	
Plan assets Money market funds Mutual funds Fixed income funds Investments measured at net asset value	\$	16,306 - - 16,306	\$	271,363 238,108 509,471	\$	- - - -	\$ \$	16,306 271,363 238,108 525,777 398,550 924,327	M M M	

(1) The three valuation techniques are market approach (M), cost approach (C), and income approach (I), as discussed in Note 2.

The Overlook Division and General Division postretirement plans are unfunded. The Overlook Division plan has an aggregate benefit obligation of \$4,932 and \$6,283 at December 31, 2024 and 2023, respectively. The General Division plan has an aggregate benefit obligation of \$636 and \$710 at December 31, 2024 and 2023, respectively.

The following tables summarize the Morristown Division's postretirement plan's financial instruments, which are measured at fair value on a recurring basis by caption and by level within the valuation hierarchy as of December 31, 2024 and 2023:

2024	in Ma Id	ted Prices Active rkets for entical Assets evel 1)	Si _t	gnificant Other servable Inputs Level 2)	Significant Unobservable Inputs (Level 3)		Fair Value December 31, 2024		Valuation Technique ⁽¹⁾	
Postretirement plan assets										
Money market funds	\$	3,141	\$	-	\$	-	\$	3,141	M	
Mutual funds				81,660				81,660	M	
	\$	3,141	\$	81,660	\$		\$	84,801		

2023	in Ma Id	ted Prices Active rkets for entical Assets evel 1)	Si _t	gnificant Other servable Inputs Level 2)	Unobs In	ificant ervable puts vel 3)	Fair Value December 31, 2023		Valuation Technique ⁽¹⁾	
Postretirement plan assets Money market funds Mutual funds	\$	3,104	\$	- 83,143	\$	- -	\$	3,104 83,143	M M	
	\$	3,104	\$	83,143	\$		\$	86,247		

(1) The three valuation techniques are market approach (M), cost approach (C), and income approach (I), as discussed at Note 2.

Expected Contributions

Based on the funded status of the Cash Balance Plan as of December 31, 2024, the Hospital expects to contribute \$36,000 during fiscal year 2025. This will be evaluated on a quarterly basis. There are no required contributions to be made to the Hospital's other postretirement plans.

Defined Contribution Plan

Effective January 1, 2014, new employees hired are eligible to participate in the Atlantic Health System 403(b) Retirement Savings Plan ("the 403(b) Plan"). For those eligible for matching contributions in the 403(b) Plan, the Hospital matches up to a percentage of compensation dependent on an employee's compensation, contribution and length of service. In addition, the Hospital provides a fixed nonelective contribution to the participants equal to 2 percent of compensation to participants employed at the end of the fiscal year. The Hospital contributed \$46,866 and \$39,658 to the 403(b) Plan for the years ended December 31, 2024 and 2023, respectively. Employees may contribute up to Internal Revenue code limits.

12. Professional and General Liability Self Insurance

The Morristown, Overlook, Newton, Chilton (effective June 1, 2016) and Hackettstown (effective April 1, 2016) Divisions and the Mountainside Division (up through the date of the sale of the Mountainside Division in May 2007) are covered by the Parent for general and professional liability through the Captive.

Under this plan, for the time period January 1, 2002 to December 31, 2002 primary insurance coverage was provided for the Hospital and its employees at \$5,000 per occurrence and \$12,000 annual aggregate. For the time period January 1, 2003 to February 1, 2004 primary insurance coverage was provided at \$7,000 per occurrence and \$21,700 annual aggregate. For the time period February 1, 2004 to March 1, 2008 primary insurance coverage was provided at \$10,000 for each and every occurrence. Subsequent to March 1, 2008, the per occurrence loss limits are \$2,000 for each medical incident in respect of insured individuals, except for OBGYN medical professionals where are provided with \$3,000 for each medical incident, \$2,000 each general liability loss, and \$250 per incident with a \$25,000 aggregate limit in respect of all other covered entities where charitable immunity in accordance with the provisions of the New Jersey statutory cap applies. The coverage for all other covered entities is limited to \$10,000 without aggregate where these provisions do not apply. These policies were written on a claims-made basis. In addition to these claims-made coverages, the Hospital has obtained tail coverages from the Captive.

(in thousands)

Prior to September 1, 2004, claims relating to before January 1, 2002, were covered by the Parent under a self-insurance plan. Under this plan, primary insurance coverage is provided at \$5,000 per occurrence and \$12,000 annual aggregate. Insurance in excess of primary coverage has been purchased from commercial insurance carriers which provide general and professional liability coverage of \$70,000 per occurrence and annual aggregate for professional liability and \$70,000 per occurrence and annual aggregate for general liability. Effective September 1, 2004, the Parent's self-insurance assets and liabilities were transferred to the Captive. In conjunction with this transfer the Hospital obtained two, three-year renewable bank letters of credit for a total of \$10,000 to support the Parent's payable. The Captive is the beneficiary of the letters of credit and can only draw down on the letter of credit, after the Captive's other assets are exhausted. As of December 31, 2024 and 2023, no amounts are outstanding under the letters of credit.

As of December 31, 2024 and 2023, the undiscounted claims liability recognized by the Captive has been actuarially determined to approximate \$128,263 and \$121,447, respectively. The Captive has investments held for general and professional liability coverage of approximately \$199,002 and \$156,498 at December 31, 2024 and 2023, respectively.

The Hospital has recorded the claims liability recognized by the Captive, net of amounts related to affiliated Parent entities, in the amount of \$118,516 and \$111,971 in accrued employee benefits and other long-term liabilities and a corresponding long-term other asset for the amount recoverable from the Captive (Note 7) as of December 31, 2024 and 2023, respectively.

The Hospital is subject to claims in the ordinary course of its business. Management and its legal counsel do not believe these claims will be in excess of the recorded liability.

13. Related Party Transactions

Due from affiliates, net, as of December 31, 2024 and 2023, consists of the following and are recorded in other current assets, long-term investments and other assets, and accrued employee benefits and other, net of current portion in the consolidated balance sheets:

	2024			2023		
Other current assets						
Due from Parent	\$	57,267	\$	44,765		
Due from Atlantic Ambulance		63,510		44,053		
Due from AHSIC		42,749		25,404		
Due from CentraState		15,573		9,715		
Due from Accountable Care Organizations		2,149		2,878		
Due from affiliated foundations		213		256		
Due from Primary Care Partners		403		329		
Due from Atlantic Health Partners		427		363		
Due from Urgent Cares		2,428				
		184,719		127,763		
Less: Allowance for doubtful accounts		(22,902)		(19,424)		
		161,817		108,339		
Long-term investments and other assets (Note 7)						
CentraState intercompany loans		113,816		113,497		
AHSIC intercompany loans		112,200		117,147		
Due from affiliated foundations		52,601		55,105		
		278,617		285,749		
Accrued employee benefits and other, net of current portion						
Due to AHSIC		(1,573)		(1,889)		
Due from related parties, net	\$	438,861	\$	392,199		

The Hospital is reimbursed by the above related parties for operating costs paid by the Hospital on their behalf. These costs include but are not limited to payroll and employee benefits, office charges and supplies and other expenses of the related party as warranted. The due from affiliated foundations include amounts donated to the affiliated foundations for the benefit of the Hospital. The amounts are held by the affiliated foundations until the purpose and/or time restriction has been met.

In addition, during each of the years ended December 31, 2024 and 2023, the Hospital recorded equity transfers on the consolidated statement of operations. The equity transfers are to the Parent and other affiliated entities controlled by the Parent primarily to support the operations of and invest in those entities to further the overall continuum of care to patients.

(in thousands)

As of December 31, 2024 and December 31, 2023, the Hospital owes \$1,573 and \$1,889 to AHSIC for leasehold improvements, respectively. In addition, the Hospital, as lessee, contracts for operating leases with AHSIC. The description of leases and payments under the leases are as follows for the years ended December 31, 2024 and 2023:

	2024	2023
Medical office buildings, apartments, houses and office space for hospital employees	\$ 9,638	\$ 7,898
As of December 31, 2024, the future minimum commitments und	er these leases a	are as follows:
2025		\$ 9,773
2026		9,841
2027		9,464
2028		8,843
2029		8,330
Thereafter		58,837
Total minimum lease commitments		105,088
Less: Imputed interest		(21,340)
Present value of lease liabilities		83,748
Less: Current portion of lease liabilities		(6,545)
Long-term lease liabilities		\$ 77,203

Minimum lease commitments with related parties after 2029 include \$22,037 associated with renewal options that are reasonably certain to be exercised.

14. Commitments and Contingencies

At December 31, 2024 and 2023, information technology contracts of \$11,330 and \$8,359, respectively, and construction contracts and purchases of equipment of \$56,604 and \$73,730, respectively, exist for on-going capital projects at the various Hospital divisions.

The Hospital is subject to complaints, subpoenas, claims and litigation which have risen in the normal course of business. In addition, the Hospital is subject to reviews and investigation by various federal and state government agencies to assure compliance with applicable laws, some of which are subject to different interpretations. While the outcome of such matters cannot be determined based upon information available at this time, management, based on advice from legal counsel, believes that any loss which may arise from these actions will not have a material adverse effect on the financial position or results of operations of the Hospital.

15. Functional Expenses

The consolidated financial statements report certain expense categories that are attributable to both health care services and general and administrative functions. Therefore, the natural expenses require allocation on a reasonable basis, that is consistently applied, across functional expense category. Salaries are allocated based on a percent-to-total of program salaries and general and administrative salaries to the applicable total expense categories. Costs not directly attributable to a function, including depreciation, amortization and interest, are allocated to a function based on the same allocation rates as salaries.

Total expenses related to providing both health care services and general and administrative functions for the years ended December 31, 2024 and 2023 are as follows:

				2024	
	Program General and				
		Services	Adn	ninistrative	Total
Salaries	\$	1,691,508	\$	329,702	\$ 2,021,210
Supplies and other expenses		1,337,837		260,766	1,598,603
Employee benefits		343,628		66,979	410,607
Depreciation and amortization		153,306		29,882	183,188
Interest		46,691		9,101	55,792
Total expenses		3,572,970		696,430	4,269,400
Other components of net periodic					
benefit costs		5,843			5,843
	\$	3,578,813	\$	696,430	\$ 4,275,243
				2023	
		Program	Ge	2023 eneral and	
	_	Program Services			Total
Salaries	\$	•		neral and	\$ Total 1,831,954
Salaries Supplies and other expenses		Services	Adn	eneral and ninistrative	\$
		Services 1,546,139	Adn	eneral and ninistrative 285,815	\$ 1,831,954
Supplies and other expenses		1,546,139 1,220,119 290,879 151,044	Adn	285,815 225,547 53,771 27,921	\$ 1,831,954 1,445,666
Supplies and other expenses Employee benefits		Services 1,546,139 1,220,119 290,879	Adn	285,815 225,547 53,771	\$ 1,831,954 1,445,666 344,650
Supplies and other expenses Employee benefits Depreciation and amortization		1,546,139 1,220,119 290,879 151,044	Adn	285,815 225,547 53,771 27,921	\$ 1,831,954 1,445,666 344,650 178,965
Supplies and other expenses Employee benefits Depreciation and amortization Interest		1,546,139 1,220,119 290,879 151,044 43,343	Adn	285,815 225,547 53,771 27,921 8,012	\$ 1,831,954 1,445,666 344,650 178,965 51,355
Supplies and other expenses Employee benefits Depreciation and amortization Interest Total expenses		1,546,139 1,220,119 290,879 151,044 43,343	Adn	285,815 225,547 53,771 27,921 8,012	\$ 1,831,954 1,445,666 344,650 178,965 51,355

16. Net Assets With Donor Restrictions

Net assets with donor restrictions are as follows:

	December 31,			
		2024		2023
Research	\$	9,751	\$	9,788
Construction projects		80,347		73,773
Purchase of plant and equipment		9,565		8,884
Scholarships and education		5,105		4,946
Program services		63,922		60,880
Net assets with donor restrictions for specified purposes		168,690		158,271
Net assets with donor restrictions for permanent endowment		55,238		52,700
	\$	223,928	\$	210,971

The original gift amounts of permanent endowment investments funds are \$45,119 and \$42,582 as of December 31, 2024 and 2023, respectively.

During 2024 and 2023, net assets were released from donor restrictions by incurring expenses satisfying the restricted purpose of purchasing capital equipment in the amounts of \$21,006 and \$18,266, respectively, and other noncapital purposes in the amounts of \$15,827 and \$15,283, respectively.

17. Liquidity and Availability of Resources

Financial assets available for general expenditures within one year of the balance sheet date consist of the following:

	2024			2023		
Financial assets						
Cash and cash equivalents	\$	244,580	\$	516,839		
Patient accounts receivable, net	,	465,950	•	386,450		
Other current assets		130,406		92,476		
		840,936		995,765		
Liquidity resources						
Available line of credit		200,000		200,000		
	\$	1,040,936	\$	1,195,765		

As part of the liquidity management strategy, the Hospital structures its financial assets to be available as its general expenditures, liabilities and other obligations come due. As part of the Hospital's liquidity management plan, cash in excess of daily requirements are invested in money market funds and mutual funds.

The Hospital has current assets limited to use for debt service and thus are not reflected above. Additionally, the Hospital has board designated assets, more fully described in Note 7, which are not available for general expenditure within the next year and are also not reflected in the amounts

(in thousands)

above. However, board designated amounts could be made available, if necessary, with board approval.

The Hospital also maintains letters of credit as discussed in Note 9.

18. Subsequent Events

Subsequent events, including disclosures related to the revolving credit agreement as noted in Note 9, have been evaluated through April 11, 2025, which is the date the consolidated financial statements were issued.



AHS Hospital Corp. Consolidating Statement of Operations Year Ended December 31, 2024

(in thousands)

	Morristown Division	Overlook Division	Newton Division	Chilton Division	Hackettstown Division	AVN	Total AHS Hospital Corp.	
Revenues, gains and other support								
Net patient service revenue	\$ 2,370,650	\$ 1,128,738	\$ 228,469	\$ 355,656	\$ 158,313	\$ 66,555	\$ 4,308,381	
Other revenue	43,387	1,621	203	412	48	2,080	47,751	
Legislative funding from FEMA	479	228	49	70	31	15	872	
Net assets released from restrictions	10,565	4,524	47	605	86	-	15,827	
Total revenues, gains and other support	2,425,081	1,135,111	228,768	356,743	158,478	68,650	4,372,831	
Expenses								
Salaries	1,076,543	520,721	122,856	176,684	74,485	49,921	2,021,210	
Supplies and other expenses	913,348	417,405	78,957	118,554	61,424	8,915	1,598,603	
Employee benefits	214,516	104,935	27,328	36,203	15,324	12,301	410,607	
Depreciation and amortization	102,846	44,485	12,814	14,748	7,306	989	183,188	
Interest	30,311	13,849	2,646	5,623	3,363		55,792	
Total operating expenses	2,337,564	1,101,395	244,601	351,812	161,902	72,126	4,269,400	
Operating income (loss)	87,517	33,716	(15,833)	4,931	(3,424)	(3,476)	103,431	
Change in net unrealized gains	37,954	17,914	3,885	5,670	2,656	1,246	69,325	
Investment income, net	82,342	38,865	8,429	12,300	5,762	2,704	150,402	
Nonoperating losses, net	(3,120)	(1,472)	(319)	(466)	(218)	(102)	(5,697)	
Excess (deficiency) of revenues over expenses	\$ 204,693	\$ 89,023	\$ (3,838)	\$ 22,435	\$ 4,776	\$ 372	\$ 317,461	

.

AHS Hospital Corp. Consolidating Statement of Operations Year Ended December 31, 2023

(in thousands)

	Morristown Division	Overlook Division	Newton Division	Chilton Division	Hackettstown Division	AVN	Total AHS Hospital Corp.	
Revenues, gains and other support								
Net patient service revenue	\$ 2,154,582	\$ 1,022,159	\$ 218,894	\$ 318,969	\$ 137,197	\$ 62,105	\$	3,913,906
Other revenue	37,844	106	(238)	62	(131)	1,911		39,554
Legislative funding from FEMA	16,134	7,668	1,699	2,368	1,038	517		29,424
Net assets released from restrictions	8,155	6,547	199	309	73	-		15,283
Total revenues, gains and other support	2,216,715	1,036,480	220,554	321,708	138,177	64,533		3,998,167
Expenses								
Salaries	968,821	471,334	122,526	161,863	60,687	46,723		1,831,954
Supplies and other expenses	822,825	375,465	78,426	108,465	52,462	8,023		1,445,666
Employee benefits	177,959	87,581	24,845	30,997	12,251	11,017		344,650
Depreciation and amortization	103,550	42,115	11,881	13,938	6,554	927		178,965
Interest	28,370	12,932	2,435	4,405	3,213			51,355
Total operating expenses	2,101,525	989,427	240,113	319,668	135,167	66,690		3,852,590
Operating income (loss)	115,190	47,053	(19,559)	2,040	3,010	(2,157)		145,577
Change in net unrealized gains	158,298	75,121	16,630	23,252	11,123	5,324		289,748
Investment income, net	32,995	15,658	3,466	4,847	2,318	1,110		60,394
Nonoperating losses, net	(9,322)	(4,424)	(979)	(1,369)	(655)	(314)		(17,063)
Excess (deficiency) of revenues over expenses	\$ 297,161	\$ 133,408	\$ (442)	\$ 28,770	\$ 15,796	\$ 3,963	\$	478,656

AHS Hospital Corp. Note to Consolidating Supplemental Information Years Ended December 31, 2024 and 2023

1. Basis of Presentation – Consolidating Supplemental Information

The accompanying consolidating supplemental schedules ("Supplemental Information") for the years ended December 31, 2024 and 2023 presented on pages 42-43 are prepared to satisfy reporting requirements for acute care hospitals operating in the State of New Jersey under regulation N.J.A.C. 8.96-1.1 et seq. and are derived from the underlying accounting records used to prepare the consolidated financial statements of the Hospital. Each of the individual columns of the Supplemental Information includes the operations of the five individual acute care hospital facilities within the Hospital which operate as divisions and not as separate corporations (the "Divisions") as further disclosed within Note 1 to the Hospital's consolidated financial statements. In addition to the five hospital Divisions, is AVN, as also disclosed in Note 1 of these consolidated financial statements.

Included within the Hospital's Morristown Division column in the Supplemental Information is its wholly owned subsidiary and not-for-profit fundraising organization, MMCF (as disclosed in Note 1 of these consolidated financial statements). Accordingly, for operational purposes, management presents the operations of MMCF as part of the Morristown Division.

Within each Division presented on the Supplemental Information are allocations of certain operating expenses and nonoperating revenues, relating to the Hospital's corporate activities, which allow for elimination amounts to be excluded from the consolidating schedules. The allocated expenses are generally based on the budgeted monthly salary and non-salary expenses. Employee benefits expense is allocated based on actual salary expenditures incurred on a monthly basis, interest expense is based on the actual projects at the respective Division, which were or are being funded through long-term debt facilities, and the changes in net unrealized gains, net and nonoperating gains, net are allocated based on the actual annual total operating revenue for each Division. Also allocated to each Division are the results of operations of AMG, the physician practice plan serving all of the Hospital Divisions. AMG's results of operations are allocated across the Divisions based primarily on the geographic location of the physician practices in relation to each Division.

Other than as described above, the Supplemental Information is prepared in accordance with accounting policies described in the accompanying notes to the consolidated financial statements. This Supplemental Information is not intended to be a presentation in accordance with accounting principles generally accepted in the United States of America as a result of the exclusion of other changes in net assets without donor restrictions which are reported below the performance indicator (excess (deficiency) of revenues over expenses). The Supplemental Information is presented for purposes of additional analysis of the results of operations and is not a required part of the consolidated financial statements.